SEC Form 4 · accession 0001209191-18-048029
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Stuart Marshall
Officer — President & CEO · Director
Period of report
Aug 21, 2018
Accepted (ET)
Aug 22, 2018 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 268,146 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 1,250 shares acquired under the Miragen Therapeutics, Inc. 2016 Employee Stock Purchase Plan on August 21, 2018.